Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis

Further Publications Rheumatology

Scale-Banking for Patient Reported Outcome Measures (PROMs) Measuring Functioning in Rheumatoid Arthritis: A Daily Activities Metric

Arthritis Care Res (Hoboken)

Prodinger B, Coenen M, Hammond A, Küçükdeveci AA, Tennant EA

doi: 10.1002/acr.24503

Rheumatoid Arthritis

Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire

Ann Rheum Dis.

Gossec L, Chauvin P, Saraux A, Hudry C, Cukierman G, de Chalus T, Dreuillet C, Saulot V, Tong S, Russo-Marie F, Joubert JM7, Berenbaum F

doi: 10.1136/

COMMENTED

Rheumatoid Arthritis

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Arthritis Res Ther.

Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR

doi: 10.1186/s13075-018-1614-z.

Rheumatoid Arthritis

Measuring inflammatory foot disease in rheumatoid arthritis: development and validation of the Rheumatoid Arthritis Foot Disease Activity Index-5

Arthritis Care Res (Hoboken).

Hoque A, Gallagher K, McEntegart A, Porter D, Steultjens M, Woodburn J, Hendry GJ

doi: 10.1002/acr.24259.

Psoriatic Arthritis

Comparing the patient reported physical function outcome measures in a real-life international cohort of patients with psoriatic arthritis

Arthritis Care Res (Hoboken).

Leung YY, Orbai AM, de Wit M, Balanescu A, Dernis E, Soubrier M, Eder L, Smolen JS, Coates LC, Gossec L, ReFlap Study Group.

doi: 10.1002/acr.24139.

Rheumatoid Arthritis

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

RMD Open.

Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R

doi: 10.1136/rmdopen-2016-000416.

Rheumatoid Arthritis

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

RMD Open.

Emery P, Blanco R, Maldonado Cocco J, Chen YC, Gaich CL, DeLozier AM, de Bono S, Liu J, Rooney T, Chang CH, Dougados M

doi: 10.1136/rmdopen-2016-000410.

Psoriatic ArthritisRheumatoid ArthritisSpinal Disorders

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany

Rheumatol Int.

Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH

doi: 10.1007/s00296-018-4180-4.

Rheumatoid Arthritis

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

Ann Rheum Dis.

Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, Stoykov I, Rooney T, Bird P, Sánchez Bursón JM, Genovese MC, Combe B

doi: 10.1136/

Related content

Scale-Banking for Patient Reported Outcome Measures (PROMs) Measuring Functioning in Rheumatoid Arthritis: A Daily Activities Metric

Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Measuring inflammatory foot disease in rheumatoid arthritis: development and validation of the Rheumatoid Arthritis Foot Disease Activity Index-5

Comparing the patient reported physical function outcome measures in a real-life international cohort of patients with psoriatic arthritis

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).